Biopsy Devices Market - Strategic Insights and Forecasts (2026-2031)

The Biopsy Devices Market is anticipated to grow from USD 2.8 billion in 2026 to USD 3.9 billion by 2031. This forecast reflects a Compound Annual Growth Rate (CAGR) of 6.9% over the strategic insights period, indicating robust growth driven by various factors outlined in the report.

Product innovations are significantly driving demand, particularly vacuum-assisted and automated core-needle systems like Mammotome AutoCore and Mammotome Revolve upgrades, introduced in 2024–2025. Additionally, endoscopic ultrasound (EUS) and fine-needle biopsy enhancements, such as Cook EchoTip ClearCore approvals/launches, are increasing the need for specialized biopsy needles in gastroenterology and pulmonology procedures by expanding clinician preference for single-insertion and higher-yield tissue sampling.

While hospitals remain the dominant end-user, the market is experiencing a shift due to procedural decentralization. The move towards outpatient biopsy protocols is creating incremental demand for compact, single-use biopsy systems and site markers in imaging and dedicated diagnostic centers, thereby simplifying workflow outside traditional operating rooms.

Regulatory tightening, notably the EU MDR and elevated registration requirements in large markets such as the US FDA, China NMPA, and India CDSCO, significantly increases compliance costs for manufacturers. This environment favors larger, established suppliers with proven regulatory footprints, shifting demand towards vendors capable of navigating these stringent pathways.

The report identifies three key growth drivers: product innovation leading to higher per-procedure yield and reduced re-biopsy rates; procedural expansion through wider adoption of EUS-guided and image-guided biopsies; and the outpatient shift increasing demand for portable, single-use systems. These drivers collectively contribute to increased unit sales of needles, procedure trays, and localization devices.

Challenges include stricter regulatory pathways, such as the EU MDR, which can be a significant headwind. Additionally, while baseline U.S. tariffs on most biopsy devices are low, country-specific duties on certain medical instruments can raise total import costs, potentially making procurement departments more price-sensitive and shifting demand toward domestically or regionally manufactured alternatives.